Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ranjeet Prasad Dash, R. Jayachandra Babu & Nuggehally R. Srinivas. (2018) Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica 48:1, pages 89-108.
Read now
Read now
Chunlan Zheng, Xiufen Hu, Li Zhao, Minhui Hu & Feng Gao. (2017) Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?. Drug Design, Development and Therapy 11, pages 2957-2968.
Read now
Read now
Minhui Hu, Chunlan Zheng & Feng Gao. (2016) Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug Design, Development and Therapy 10, pages 3983-3994.
Read now
Read now
Andreas Holstein, Winfried Beil & Peter Kovacs. (2012) CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opinion on Drug Metabolism & Toxicology 8:12, pages 1549-1563.
Read now
Read now
Jeffrey S Freeman & Benjamin Gross. (2012) Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Review of Clinical Pharmacology 5:1, pages 31-42.
Read now
Read now
André J Scheen. (2011) Cytochrome P450-mediated cardiovascular drug interactions. Expert Opinion on Drug Metabolism & Toxicology 7:9, pages 1065-1082.
Read now
Read now
Andreas Holstein, Claude Hammer, Michael Hahn, Nidhi-Su-Ann Kulamadayil & Peter Kovacs. (2010) Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opinion on Drug Safety 9:5, pages 675-681.
Read now
Read now
Articles from other publishers (38)
Hanna S. Abbo, Divine M. Yufanyi, Tariq Shah, Nader G. Khaligh, Sampath Chinnam, Thomas Efferth & Salam J. J. Titinchi. (2023) Curcuminoid Nanovesicles as Advanced Therapeutics. ChemBioEng Reviews.
Crossref
Crossref
Aikaterini Saiti, Alexandros Giannopoulos-Dimitriou, Ioannis Kazakos, Eleftheria Galatou & Ioannis S. Vizirianakis. (2023) Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. Future Pharmacology 3:1, pages 329-363.
Crossref
Crossref
Elza Sundhani, Agung Endro Nugroho, Arief Nurrochmad, Ika Puspitasari, Dita Amalia Prihati & Endang Lukitaningsih. (2022) Pharmacokinetic Herb-Drug Interactions of Glipizide with Andrographis paniculata (Burm. f.) and Andrographolide in Normal and Diabetic Rats by Validated HPLC Method. Molecules 27:20, pages 6901.
Crossref
Crossref
Jia-Xu Li & Carolyn L. Cummins. (2022) Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nature Reviews Endocrinology 18:9, pages 540-557.
Crossref
Crossref
Elza Sundhani, Endang Lukitaningsih, Arief Nurrochmad & Agung Endro Nugroho. (2022) Potential pharmacokinetic and pharmacodynamic herb-drug interactions of Andrographis paniculata (Burm. f.) and andrographolide: A systematic review. Journal of Herbmed Pharmacology 11:2, pages 154-165.
Crossref
Crossref
Guyi Wang, Bing Xiao, Jiayi Deng, Linmei Gong, Yi Li, Jinxiu Li & Yanjun Zhong. (2022) The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy. Frontiers in Pharmacology 13.
Crossref
Crossref
Tanja Dujic, Sandra Cvijic, Amar Elezovic, Tamer Bego, Selma Imamovic Kadric, Maja Malenica, Alisa Elezovic, Ewan R. Pearson & Aida Kulo. (2021) Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. Journal of Personalized Medicine 11:5, pages 367.
Crossref
Crossref
Bee Ling Tan & Mohd Esa NorhaizanBee Ling Tan & Mohd Esa Norhaizan. 2021. The Role of Antioxidants in Longevity and Age-Related Diseases. The Role of Antioxidants in Longevity and Age-Related Diseases
81
156
.
Catarina Andrade, Nelson G.M. Gomes, Sutsawat Duangsrisai, Paula B. Andrade, David M. Pereira & Patrícia Valentão. (2020) Medicinal plants utilized in Thai Traditional Medicine for diabetes treatment: Ethnobotanical surveys, scientific evidence and phytochemicals. Journal of Ethnopharmacology 263, pages 113177.
Crossref
Crossref
Tapan Kumar Giri, Payel Roy & Subhasis Maity. (2020) Formulation and Characterization of Solid Dispersion Containing Capsaicin for the Treatment of Diabetes. Current Drug Therapy 15:3, pages 219-225.
Crossref
Crossref
Derek LeRoith, Geert Jan Biessels, Susan S Braithwaite, Felipe F Casanueva, Boris Draznin, Jeffrey B Halter, Irl B Hirsch, Marie E McDonnell, Mark E Molitch, M Hassan Murad & Alan J Sinclair. (2019) Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 104:5, pages 1520-1574.
Crossref
Crossref
Lindokuhle Patience Mabuza, Mlindeli Wilkinson Gamede, Sanam Maikoo, Irvin Noel Booysen, Phikelelani Siphosethu Nguban & Andile Khathi. (2019) Hepatoprotective Effects of a Ruthenium(II) Schiff Base Complex in Rats with Diet-Induced Prediabetes. Current Therapeutic Research 91, pages 66-72.
Crossref
Crossref
Susana Rivera-Mancía, Joyce Trujillo & José Pedraza Chaverri. (2018) Utility of curcumin for the treatment of diabetes mellitus: Evidence from preclinical and clinical studies. Journal of Nutrition & Intermediary Metabolism 14, pages 29-41.
Crossref
Crossref
Chayakrit Krittanawong, Andrew Xanthopoulos, Takeshi Kitai, Natalia Branis, HongJu Zhang & Marrick Kukin. (2017) DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics. Heart Failure Reviews 23:3, pages 355-361.
Crossref
Crossref
Sarah Maximos, Michel Chamoun, Sophie Gravel, Jacques Turgeon & Veronique Michaud. (2017) Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics 9:4, pages 40.
Crossref
Crossref
X. Li & Z.Q. Liu. 2017. Drug Metabolism in Diseases. Drug Metabolism in Diseases
157
179
.
Amisha Wallia, Vidhya Illuri & Mark E. Molitch. (2016) Diabetes Care After Transplant. Medical Clinics of North America 100:3, pages 535-550.
Crossref
Crossref
Yassine Réggami, Hajira Berredjem, Hadjer Cheloufi, Malika Berredjem & Noureddine Bouzerna. (2016) Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats. European Journal of Pharmacology 779, pages 122-130.
Crossref
Crossref
Marcus May & Christoph Schindler. (2016) Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism 7:2, pages 69-83.
Crossref
Crossref
Allison J. Hahr & Mark E. Molitch. (2015) Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology 1:1.
Crossref
Crossref
Florence Ranchon, Thierry Vial, Catherine Rioufol, Emilie Hénin, Claire Falandry, Gilles Freyer, Véronique Trillet-Lenoir, Christophe Le Tourneau & Benoit You. (2015) Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials. Critical Reviews in Oncology/Hematology 94:2, pages 189-200.
Crossref
Crossref
Muhammad Amin & Naeti Suksomboon. (2014) Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions. Drug Safety 37:11, pages 903-919.
Crossref
Crossref
Allison J. Hahr & Mark E. Molitch. 2014. Diabetes and Kidney Disease. Diabetes and Kidney Disease
205
214
.
Patricio Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes Georg Bode, Jennifer Bolleyn, Christoph Borner, Jan Böttger, Albert Braeuning, Robert A. Budinsky, Britta Burkhardt, Neil R. Cameron, Giovanni Camussi, Chong-Su Cho, Yun-Jaie Choi, J. Craig Rowlands, Uta Dahmen, Georg Damm, Olaf Dirsch, María Teresa Donato, Jian Dong, Steven Dooley, Dirk Drasdo, Rowena Eakins, Karine Sá Ferreira, Valentina Fonsato, Joanna Fraczek, Rolf Gebhardt, Andrew Gibson, Matthias Glanemann, Chris E. P. Goldring, María José Gómez-Lechón, Geny M. M. Groothuis, Lena Gustavsson, Christelle Guyot, David Hallifax, Seddik Hammad, Adam Hayward, Dieter Häussinger, Claus Hellerbrand, Philip Hewitt, Stefan Hoehme, Hermann-Georg Holzhütter, J. Brian Houston, Jens Hrach, Kiyomi Ito, Hartmut Jaeschke, Verena Keitel, Jens M. Kelm, B. Kevin Park, Claus Kordes, Gerd A. Kullak-Ublick, Edward L. LeCluyse, Peng Lu, Jennifer Luebke-Wheeler, Anna Lutz, Daniel J. Maltman, Madlen Matz-Soja, Patrick McMullen, Irmgard Merfort, Simon Messner, Christoph Meyer, Jessica Mwinyi, Dean J. Naisbitt, Andreas K. Nussler, Peter Olinga, Francesco Pampaloni, Jingbo Pi, Linda Pluta, Stefan A. Przyborski, Anup Ramachandran, Vera Rogiers, Cliff Rowe, Celine Schelcher, Kathrin Schmich, Michael Schwarz, Bijay Singh, Ernst H. K. Stelzer, Bruno Stieger, Regina Stöber, Yuichi Sugiyama, Ciro Tetta, Wolfgang E. Thasler, Tamara Vanhaecke, Mathieu Vinken, Thomas S. Weiss, Agata Widera, Courtney G. Woods, Jinghai James Xu, Kathy M. Yarborough & Jan G. Hengstler. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 87:8, pages 1315-1530.
Crossref
Crossref
Alexander Sämann & Ulrich A. Müller. 2013. Diabetes and Kidney Disease. Diabetes and Kidney Disease
186
201
.
Gaia Chiara Mannino & Giorgio Sesti. (2012) Individualized Therapy for Type 2 Diabetes. Molecular Diagnosis & Therapy 16:5, pages 285-302.
Crossref
Crossref
Aleksi Tornio, Mikko Niemi, Pertti J. Neuvonen & Janne T. Backman. (2012) Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences 33:6, pages 312-322.
Crossref
Crossref
A. Holstein, Th. Duning, W. Kleophas, Ch. A. Schneider & Heinz-Jürgen Rüßmann. (2012) Wie kann dieser Notfall verhindert werden?. MMW - Fortschritte der Medizin 154:8, pages 62-69.
Crossref
Crossref
Vita Dolžan. 2012. Pharmacogenetics and Individualized Therapy. Pharmacogenetics and Individualized Therapy
13
80
.
Lisa E. Hines & John E. Murphy. (2011) Potentially Harmful Drug–Drug Interactions in the Elderly: A Review. The American Journal of Geriatric Pharmacotherapy 9:6, pages 364-377.
Crossref
Crossref
Hao Sun & Dennis O. Scott. (2011) Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chemico-Biological Interactions 194:2-3, pages 159-167.
Crossref
Crossref
F. Andreelli, D. Jacquier, A. Dierick-Gallet & C. Amouyal. (2011) Pharmacogénétique des antidiabétiques. Médecine des Maladies Métaboliques 5:5, pages 512-519.
Crossref
Crossref
Vangelis G Manolopoulos, Georgia Ragia & Anna Tavridou. (2011) Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 12:8, pages 1161-1191.
Crossref
Crossref
A. Holstein. (2011) Impact of renal impairment on the risk of severe hypoglycaemia associated with the use of insulin and glyburide. Nephrology Dialysis Transplantation 26:5, pages 1748-1749.
Crossref
Crossref
Andreas HolsteinAngela Seeringer & Peter Kovacs. (2011) Therapy with oral antidiabetic drugs: applied pharmacogenetics. The British Journal of Diabetes & Vascular Disease 11:1, pages 10-16.
Crossref
Crossref
Jing Li, Martin H. Bluth & Andrea Ferreira-Gonzalez. 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods. Henry's Clinical Diagnosis and Management by Laboratory Methods
1359
1382
.
André J. Scheen. (2010) Dipeptidylpeptitase-4 Inhibitors (Gliptins). Clinical Pharmacokinetics 49:9, pages 573-588.
Crossref
Crossref
H Schelleman, W B Bilker, C M Brensinger, F Wan & S Hennessy. (2010) Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide. Clinical Pharmacology & Therapeutics 88:2, pages 214-222.
Crossref
Crossref